癌症治疗公司CG Oncology(CGON)股价大涨9.1%,此前古根海姆证券以“买入”评级开始覆盖该股,其目标价预示巨大上涨空间。该投行表示看好CG公司针对非肌层浸润性膀胱癌的疗法前景。
责任编辑:张俊 SF065
癌症治疗公司CG Oncology(CGON)股价大涨9.1%,此前古根海姆证券以“买入”评级开始覆盖该股,其目标价预示巨大上涨空间。该投行表示看好CG公司针对非肌层浸润性膀胱癌的疗法前景。
责任编辑:张俊 SF065
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.